

Hindu, Delhi

Saturday 10th May 2014, Page: 13

Width: 4.29 cms, Height: 10.13 cms, a4, Ref: pmln.2014-05-10.42.121

## Ranbaxy reports loss ahead of Sun Pharma deal

**NEW DELHI:** Ranbaxy Laboratories, being acquired by Sun Pharmaceuticals for \$3.2 billion, on Friday posted a loss in the January-March quarter due to rise in finance cost and write-off related to regulatory sanctions. Ranbaxy reported a consolidated net loss of Rs.73.65 crore in January-March as against Rs.125.75 crore profit in the same period last year. Sales were impacted due to a recent import ban by U.S. regulators on its plants on concerns of poor manufacturing quality. The firm made a provision of Rs.62.95 crore for inventory write-off and other costs related to the January ban imposed by the U.S. Food and Drug Administration. — PTI

Con/amy

891